View Financial HealthChengDa Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 1/6ChengDa Pharmaceuticals 은(는) 현재 수익률이 0.53% 인 배당금 지급 회사입니다.핵심 정보0.5%배당 수익률0.007%자사주 매입 수익률총 주주 수익률0.5%미래 배당 수익률n/a배당 성장률-8.2%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향-859%최근 배당 및 자사주 매입 업데이트Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.분석 기사 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.공시 • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.공시 • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.모든 업데이트 보기Recent updatesReported Earnings • Apr 28Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024)Full year 2025 results: CN¥0.079 loss per share (improved from CN¥0.18 loss in FY 2024). Revenue: CN¥406.4m (up 22% from FY 2024). Net loss: CN¥11.9m (loss narrowed 58% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.공시 • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.10 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.026 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥102.6m (up 29% from 3Q 2024). Net income: CN¥3.95m (down 74% from 3Q 2024). Profit margin: 3.8% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 39% per year over the past 5 years.Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CN¥0.094 (vs CN¥0.043 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.094 (up from CN¥0.043 in 2Q 2024). Revenue: CN¥106.1m (up 68% from 2Q 2024). Net income: CN¥14.2m (up 118% from 2Q 2024). Profit margin: 13% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.공시 • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • May 16New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years.Reported Earnings • Apr 25First quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.12 profit in 1Q 2024)First quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.12 profit in 1Q 2024). Revenue: CN¥76.3m (down 24% from 1Q 2024). Net loss: CN¥1.40m (down 108% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.공시 • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang ChinaNew Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.7% per year over the past 5 years. High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change).Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥24.29, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 57% over the past three years.공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.분석 기사 • Oct 08ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With EarningsChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) shareholders have had their patience rewarded with a 42% share price...분석 기사 • Oct 08There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price JumpThe ChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) share price has done very well over the last month, posting an...공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.분석 기사 • Sep 03ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for ChengDa Pharmaceuticals Co., Ltd.'s ( SZSE:301201 ) stock hasn't...Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.분석 기사 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past year.공시 • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year.Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past year.공시 • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past year.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 36% over the past year.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to CN¥26.09, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past year.공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.공시 • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥88.4m (down 6.6% from 3Q 2021). Net income: CN¥27.0m (up 38% from 3Q 2021). Profit margin: 31% (up from 21% in 3Q 2021). The increase in margin was driven by lower expenses.Reported Earnings • Aug 15Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥108.6m (up 15% from 2Q 2021). Net income: CN¥38.9m (up 99% from 2Q 2021). Profit margin: 36% (up from 21% in 2Q 2021). The increase in margin was primarily driven by higher revenue.공시 • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.공시 • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.공시 • Apr 20ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend for the Year 2021ChengDa Pharmaceuticals Co., Ltd. announced final dividend proposal of CNY 4.50000000 per 10 shares (tax included) for the year 2021.Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥102, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 27% share price gain to CN¥91.01, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 301201 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: 301201 4 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장ChengDa Pharmaceuticals 배당 수익률 vs 시장301201의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (301201)0.5%시장 하위 25% (CN)0.4%시장 상위 25% (CN)2.3%업계 평균 (Pharmaceuticals)2.3%분석가 예측 (301201) (최대 3년)n/a주목할만한 배당금: 301201 의 배당금( 0.53% )은 CN 시장에서 배당금 지급자의 하위 25%( 0.38% )보다 높습니다.고배당: 301201 의 배당금( 0.53% )은 CN 시장에서 배당금 지급자의 상위 25%( 2.26% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 301201 배당금을 지급하고 있지만 회사는 수익성이 없습니다.주주 현금 배당현금 흐름 범위: 301201 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 17:50종가2026/06/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChengDa Pharmaceuticals Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.
분석 기사 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
공시 • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.
공시 • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.
Reported Earnings • Apr 28Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024)Full year 2025 results: CN¥0.079 loss per share (improved from CN¥0.18 loss in FY 2024). Revenue: CN¥406.4m (up 22% from FY 2024). Net loss: CN¥11.9m (loss narrowed 58% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
공시 • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.
Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.10 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.026 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥102.6m (up 29% from 3Q 2024). Net income: CN¥3.95m (down 74% from 3Q 2024). Profit margin: 3.8% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 39% per year over the past 5 years.
Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CN¥0.094 (vs CN¥0.043 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.094 (up from CN¥0.043 in 2Q 2024). Revenue: CN¥106.1m (up 68% from 2Q 2024). Net income: CN¥14.2m (up 118% from 2Q 2024). Profit margin: 13% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.
공시 • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • May 16New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years.
Reported Earnings • Apr 25First quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.12 profit in 1Q 2024)First quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.12 profit in 1Q 2024). Revenue: CN¥76.3m (down 24% from 1Q 2024). Net loss: CN¥1.40m (down 108% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
공시 • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.7% per year over the past 5 years. High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change).
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥24.29, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 57% over the past three years.
공시 • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
공시 • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.
분석 기사 • Oct 08ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With EarningsChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) shareholders have had their patience rewarded with a 42% share price...
분석 기사 • Oct 08There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price JumpThe ChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) share price has done very well over the last month, posting an...
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.
분석 기사 • Sep 03ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for ChengDa Pharmaceuticals Co., Ltd.'s ( SZSE:301201 ) stock hasn't...
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
분석 기사 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).
Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past year.
공시 • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year.
Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past year.
공시 • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past year.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).
공시 • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 36% over the past year.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to CN¥26.09, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past year.
공시 • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
공시 • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.
Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).
Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥88.4m (down 6.6% from 3Q 2021). Net income: CN¥27.0m (up 38% from 3Q 2021). Profit margin: 31% (up from 21% in 3Q 2021). The increase in margin was driven by lower expenses.
Reported Earnings • Aug 15Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥108.6m (up 15% from 2Q 2021). Net income: CN¥38.9m (up 99% from 2Q 2021). Profit margin: 36% (up from 21% in 2Q 2021). The increase in margin was primarily driven by higher revenue.
공시 • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.
공시 • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.
공시 • Apr 20ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend for the Year 2021ChengDa Pharmaceuticals Co., Ltd. announced final dividend proposal of CNY 4.50000000 per 10 shares (tax included) for the year 2021.
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥102, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 27% share price gain to CN¥91.01, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China.